Docetaxel With or Without Oblimersen in Treating Patients With Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00030641. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Study of Docetaxel Versus Docetaxel Plus Genasense™ (G3139; Bcl-2 Antisense Oligonucleotide) in Patients With Previously Treated Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
RATIONALE: Drugs used in chemotherapy such as docetaxel use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of docetaxel by making the tumor cells more sensitive to the drug. It is not yet known if docetaxel is more effective with or without oblimersen in treating non-small cell lung cancer. PURPOSE: Randomized phase II/III trial to compare the effectiveness of docetaxel with or without oblimersen in treating patients who have relapsed or refractory non-small cell lung cancer that has been previously treated.
Study identification
- NCT ID
- NCT00030641
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- Not listed
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 2001 (Type not available)
- Primary completion
- Not listed
- Completion
- Not listed
- Last update posted
- Jan 6, 2014
Started 2001
United States locations
- U.S. sites
- 35
- U.S. states
- 20
- U.S. cities
- 33
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham Comprehensive Cancer Center | Birmingham | Alabama | 35294-3300 | — |
| Montgomery Cancer Center | Montgomery | Alabama | 36106-2801 | — |
| Little Rock Hematology-Oncology Associates | Little Rock | Arkansas | 72205 | — |
| East Bay Medical Oncology | Concord | California | 94520 | — |
| Jonsson Comprehensive Cancer Center, UCLA | Los Angeles | California | 90095 | — |
| Medical Oncology Care Associates | Orange | California | 92868 | — |
| Pacific Hematology/Oncology | San Francisco | California | 94115 | — |
| John Wayne Cancer Institute at Saint John's Health Center | Santa Monica | California | 90404 | — |
| University of Colorado Cancer Center at University of Colorado Health Sciences Center | Aurora | Colorado | 80010 | — |
| Whittingham Cancer Center | Norwalk | Connecticut | 06856 | — |
| Lakeland Regional Cancer Center | Lakeland | Florida | 33805 | — |
| Georgia Cancer Specialists - Northside Office | Atlanta | Georgia | 30342 | — |
| Augusta Oncology Associates | Augusta | Georgia | 30901 | — |
| University of Chicago Cancer Research Center | Chicago | Illinois | 60637 | — |
| CCOP - Northern Indiana CR Consortium | South Bend | Indiana | 46601 | — |
| Central Baptist Hospital | Lexington | Kentucky | 40503 | — |
| Hematology Oncology Services | New Orleans | Louisiana | 70115 | — |
| Louisiana State University Health Sciences Center - Shreveport | Shreveport | Louisiana | 71130-3932 | — |
| Josephine Ford Cancer Center at Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Methodist Hospital Cancer Center at Nebraska Methodist Hospital - Omaha | Omaha | Nebraska | 68114-4199 | — |
| Summit Medical Group, P.A. | Summit | New Jersey | 07901 | — |
| Winthrop University Hospital | Mineola | New York | 11501 | — |
| North General Hospital | New York | New York | 10035 | — |
| Veterans Affairs Medical Center - Oklahoma City | Oklahoma City | Oklahoma | 73104 | — |
| Charleston Cancer Center | Charleston | South Carolina | 29406 | — |
| Arlington Cancer Center | Arlington | Texas | 76012-2510 | — |
| Medical City Dallas Hospital | Dallas | Texas | 75230 | — |
| Harold Simmons Cancer Center | Dallas | Texas | 75390-8852 | — |
| University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| Joe Arrington Cancer Research and Treatment Center | Lubbock | Texas | 79410-1894 | — |
| Texas Cancer Care | Weatherford | Texas | 76086 | — |
| Madigan Army Medical Center | Tacoma | Washington | 98431-5048 | — |
| Yakima Regional Cancer Care Center | Yakima | Washington | 98902 | — |
| Morgantown Internal Medicine Group | Morgantown | West Virginia | 26505 | — |
| West Virginia University Hospitals | Morgantown | West Virginia | 26506-9162 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00030641, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2014 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00030641 live on ClinicalTrials.gov.